Pennsylvania is currently home to 3298 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics
NCT05490888
Recruiting
This 2-part study will evaluate PHIN-214 given as a single one-time dose (Part 1) and in multiple doses (given as daily doses for 28-days) (in Part 2). Specifically, this study evaluates PHIN-214, to determine the safety, tolerability, and pharmacokinetic effects of PHIN-214, and to establish the maximum tolerated dose or optimal beneficial dose in patients with Child Pugh A and B Cirrhosis.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/21/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Cirrhosis, Liver, Liver Fibrosis, Ascites Hepatic
Register for Updates
Effect of Music Therapy on Infants with Neonatal Abstinence Syndrome
NCT03533985
Recruiting
This study examines the effects of 6 different music therapy interventions on outcomes for neonates diagnosed with Neonatal Abstinence Syndrome.
Gender:
ALL
Ages:
28 weeks and above
Trial Updated:
02/21/2025
Locations: Drexel University/Hahnemann Hospital-College of Nursing and Health Professions, Philadelphia, Pennsylvania
Conditions: NAS
Register for Updates
Teaching Harm Reduction in a Hospital Setting: A Peer-led Intervention
NCT06843213
Recruiting
The purpose of the study is to develop an acceptable, feasible, and effective peer-led bundle of harm reduction services to be delivered in the hospital setting, called the THRIVE intervention. The main question it aims to answer is: Will participants receiving the THRIVE intervention have a reduced risk of self-reported non-fatal overdoses OR skin/soft tissue infections compared to participants receiving enhanced usual care? Researchers will compare the THRIVE model to enhanced usual care to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: UPMC Mercy Hospital, Pittsburgh, Pennsylvania
Conditions: Opioid Use Disorder, Harm Reduction
Register for Updates
CARE Study: Cancer, Asian Americans, and Relationship Enrichment
NCT06782581
Recruiting
The overarching goal of the current study is to reduce the burden Asian American patients may feel are on their caregivers by designing and testing the feasibility and efficacy of a positive activity intervention designed to increase a sense of autonomy, competence, and connectedness, each of which have been shown to be associated with psychological benefits according to self-determination theory.
Gender:
ALL
Ages:
Between 21 years and 80 years
Trial Updated:
02/20/2025
Locations: Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania
Conditions: Neoplasm
Register for Updates
Efficacy and Safety Study of OATD-01 in Patients with Active Pulmonary Sarcoidosis
NCT06205121
Recruiting
This is a Phase 2, randomized, double-blind, placebo-controlled, adaptive, multicenter study to evaluate the efficacy, safety, tolerability, Pharmacodynamics (PD), and Pharmacokinetics (PK) of OATD-01 in the treatment of subjects with active pulmonary sarcoidosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: Molecure Investigative Site, Philadelphia, Pennsylvania
Conditions: Pulmonary Sarcoidosis
Register for Updates
Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG
NCT05555550
Recruiting
The purpose of this study is to see if 18F-Fluciclovine (Axumin®) is useful and safe in the management of children with Low Grade Gliomas (LGG). Imaging with 18F-Fluciclovine PET-MRI will be performed prior to initiation of therapy for LGG, and then 3 months, and 1 year after starting therapy. Changes in 18F-Fluciclovine uptake will be compared to changes in MRI measurements at 3 months and 1 year as compared to baseline.
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
02/20/2025
Locations: The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Glioma, Low-grade Glioma, Low Grade Glioma of Brain, Glioma, Malignant, Glioma Intracranial
Register for Updates
Gastric Ultrasound in Pediatric Trauma Patients
NCT05330351
Recruiting
Gastric ultrasound has become increasingly utilized to examine volume and quality of gastric contents in the preoperative setting to guide anesthetic management and relay risk of aspiration in both adult and pediatric medicine. Gastric fluid volumes in trauma patients are thought to be elevated due to delayed gastric emptying in the setting of an over-attenuated sympathetic response to physical pain and stress, opioid analgesia, and other associated injuries (traumatic brain). However, there is... Read More
Gender:
ALL
Ages:
Between 0 years and 17 years
Trial Updated:
02/20/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Trauma; Complications, Aspiration
Register for Updates
Trial of Pre-operative Neratinib and Endocrine Therapy with Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
NCT04886531
Recruiting
Patient will be treated with neratinib, an aromatase inhibitor and trastuzumab for 24 weeks prior to surgery, following an initial 3 weeks of neratinib alone, aromatase inhibitor alone or the combination of neratinib and an aromatase inhibitor. A breast biopsy will be performed prior to Day 1 of week 4 of treatment. Following surgery, patients will receive standard of care HER2-directed and endocrine therapy at the treating physician's discretion.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: Penn State Cancer Institute, Hershey, Pennsylvania
Conditions: Breast Cancer, HER2-positive Breast Cancer, ER Positive Breast Cancer, PR-Positive Breast Cancer
Register for Updates
HM15136 (efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years with Congenital Hyperinsulinism (CHI)
NCT04732416
Recruiting
This study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of HM15136 when used as add-on therapy in subjects with CHI with persistent hypoglycemia while on standard of care treatment (SoC). HM15136 will be administered once weekly in multiple doses to subjects in multiple age including pediatric to find appropriate exposure-response data.
Gender:
ALL
Ages:
2 years and above
Trial Updated:
02/20/2025
Locations: The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Congenital Hyperinsulinism
Register for Updates
[18F]Fluoropropyl-Trimethoprim ([18F]F-TMP) PET/CT Imaging to Evaluate Biodistribution and Kinetics in Human Subjects
NCT04263792
Recruiting
The purpose of this study is to study a radioactive tracer, a type of imaging drug that is injected into the body to see how it is taken up in sites of active infection using an imaging procedure called Positron Emission Tomography/Computed Tomography (PET/CT).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Bacterial Infections
Register for Updates
Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder
NCT06701903
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of ITI-1284 as monotherapy treatment in patients meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for GAD in patients who have had inadequate response to generalized anxiety disorder treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/19/2025
Locations: Clinical Site, Media, Pennsylvania
Conditions: Generalized Anxiety Disorder
Register for Updates
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
NCT06480383
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of ITI-1284 compared with placebo as adjunctive therapy to GAD treatment in patients meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for GAD who have an inadequate response to ongoing GAD treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/19/2025
Locations: Clinical Site, Allentown, Pennsylvania
Conditions: Generalized Anxiety Disorder
Register for Updates